First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR -mutated lung cancer: a single institution's clinical practice experience-Reference-Cited by-同舟云学术

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR -mutated lung cancer: a single institution's clinical practice experience

Published:2018-07-28 Issue:1 Volume:38 Page:51
ISSN:2523-3548
Container-title:Cancer Communications
language:en
Short-container-title:Cancer Communications

Author:

Yu Xiangyang¹²,Zhang Xuewen¹³,Zhang Zichen¹⁴,Lin Yongbin¹²,Wen Yingsheng¹²,Chen Yongqiang¹²,Wang Weidong¹²,Zhang Lanjun¹²^ORCID

Affiliation:

1. State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine; Guangzhou 510060 Guangdong China

2. Department of Thoracic Surgery; Sun Yat-sen University Cancer Center; 651 Dongfeng Road East Guangzhou 510060 Guangdong China

3. Department of Medical Oncology; Sun Yat-sen University Cancer Center; Guangzhou 510060 Guangdong China

4. Department of Molecular Pathology; Sun Yat-sen University Cancer Center; Guangzhou 510060 Guangdong China

Funder

National Key Research and Development Plan

National Basic Research Program of China

Ministry of Science and Technology of the People's Republic of China

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1186/s40880-018-0321-0.pdf

Reference58 articles.

1. NCCN clinical practice guidelines in oncology (NCCN guidelines) non-small cell lung cancer, version 4 2017

2. Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities;Gaughan;Ther Adv Med Oncol.,2011

3. Epidermal growth factor receptor mutations in lung cancer;Sharma;Nat Rev Cancer,2007

4. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma;Mok;N Engl J Med.,2009

5. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol.,2011

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review;Journal of Thoracic Oncology;2024-07

2. Furmonertinib and intrathecal pemetrexed chemotherapy rechallenges osimertinib-refractory leptomeningeal metastasis in a non-small cell lung cancer patient harboring EGFR20 R776S, C797S, and EGFR21 L858R compound EGFR mutations: a case report;Anti-Cancer Drugs;2024-03-15

3. Successful treatment of lung adenocarcinoma complicated with a rare compound EGFR mutation L833V/H835L using aumolertinib: a case report and literature review;Frontiers in Pharmacology;2023-08-29

4. HDACIs and TKIs combinations and their liposomal delivery for cancer treatment;Journal of Controlled Release;2023-06

5. Overview on Therapeutic Options in Uncommon EGFR Mutant Non-Small Cell Lung Cancer (NSCLC): New Lights for an Unmet Medical Need;International Journal of Molecular Sciences;2023-05-17